» Articles » PMID: 36795730

Aging Decreases Docosahexaenoic Acid Transport Across the Blood-brain Barrier in C57BL/6J Mice

Overview
Journal PLoS One
Date 2023 Feb 16
PMID 36795730
Authors
Affiliations
Soon will be listed here.
Abstract

Nutrients are actively taken up by the brain via various transporters at the blood-brain barrier (BBB). A lack of specific nutrients in the aged brain, including decreased levels of docosahexaenoic acid (DHA), is associated with memory and cognitive dysfunction. To compensate for decreased brain DHA, orally supplied DHA must be transported from the circulating blood to the brain across the BBB through transport carriers, including major facilitator superfamily domain-containing protein 2a (MFSD2A) and fatty acid-binding protein 5 (FABP5) that transport esterified and non-esterified DHA, respectively. Although it is known that the integrity of the BBB is altered during aging, the impact of aging on DHA transport across the BBB has not been fully elucidated. We used 2-, 8-, 12-, and 24-month-old male C57BL/6 mice to evaluate brain uptake of [14C]DHA, as the non-esterified form, using an in situ transcardiac brain perfusion technique. Primary culture of rat brain endothelial cells (RBECs) was used to evaluate the effect of siRNA-mediated MFSD2A knockdown on cellular uptake of [14C]DHA. We observed that the 12- and 24-month-old mice exhibited significant reductions in brain uptake of [14C]DHA and decreased MFSD2A protein expression in the brain microvasculature compared with that of the 2-month-old mice; nevertheless, FABP5 protein expression was up-regulated with age. Brain uptake of [14C]DHA was inhibited by excess unlabeled DHA in 2-month-old mice. Transfection of MFSD2A siRNA into RBECs decreased the MFSD2A protein expression levels by 30% and reduced cellular uptake of [14C]DHA by 20%. These results suggest that MFSD2A is involved in non-esterified DHA transport at the BBB. Therefore, the decreased DHA transport across the BBB that occurs with aging could be due to age-related down-regulation of MFSD2A rather than FABP5.

Citing Articles

Lipidomics Analysis Reveals the Effects of Docosahexaenoic Acid from Different Sources on Prefrontal-Cortex Synaptic Plasticity.

He Z, Xiong W, Yang Y, Zhang Y, Li B, Wang F Nutrients. 2025; 17(3).

PMID: 39940315 PMC: 11819862. DOI: 10.3390/nu17030457.


Interaction of major facilitator superfamily domain containing 2A with the blood-brain barrier.

Ma Y, Dong T, Luan F, Yang J, Miao F, Wei P Neural Regen Res. 2024; 20(8):2133-2152.

PMID: 39248155 PMC: 11759009. DOI: 10.4103/NRR.NRR-D-24-00191.


Effects of APOE4 on omega-3 brain metabolism across the lifespan.

Ebright B, Duro M, Chen K, Louie S, Yassine H Trends Endocrinol Metab. 2024; 35(8):745-757.

PMID: 38609814 PMC: 11321946. DOI: 10.1016/j.tem.2024.03.003.


The Expression of Major Facilitator Superfamily Domain-Containing Protein2a (Mfsd2a) and Aquaporin 4 Is Altered in the Retinas of a 5xFAD Mouse Model of Alzheimer's Disease.

Jovanovic Macura I, Zivanovic A, Perovic M, Ciric J, Major T, Kanazir S Int J Mol Sci. 2023; 24(18).

PMID: 37762391 PMC: 10531902. DOI: 10.3390/ijms241814092.

References
1.
Verheggen I, de Jong J, van Boxtel M, Gronenschild E, Palm W, Postma A . Increase in blood-brain barrier leakage in healthy, older adults. Geroscience. 2020; 42(4):1183-1193. PMC: 7394987. DOI: 10.1007/s11357-020-00211-2. View

2.
Zlokovic B . The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008; 57(2):178-201. DOI: 10.1016/j.neuron.2008.01.003. View

3.
Pu L, Igbavboa U, Wood W, Roths J, Kier A, Spener F . Expression of fatty acid binding proteins is altered in aged mouse brain. Mol Cell Biochem. 1999; 198(1-2):69-78. DOI: 10.1023/a:1006946027619. View

4.
Conquer J, Holub B . Effect of supplementation with different doses of DHA on the levels of circulating DHA as non-esterified fatty acid in subjects of Asian Indian background. J Lipid Res. 1998; 39(2):286-92. View

5.
Jicha G, Markesbery W . Omega-3 fatty acids: potential role in the management of early Alzheimer's disease. Clin Interv Aging. 2010; 5:45-61. PMC: 2854051. DOI: 10.2147/cia.s5231. View